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Bradykinin (BK) has been tobe thought a potent mediator involved in allergic rhinitis because BK was recovered from the nasal
lavage ﬂuid of allergic rhinitis patients after allergen provocation and BK receptor antagonists relief nasal allergic symptoms. Two
mammalian BK receptor subtypes, B1 and B2, have been deﬁned based on their pharmacological properties. We investigated the
localization of these receptors by immunohistochemistry. Human turbinates were obtained after turbinectomy from 12 patients
with nasal obstruction refractory to medical therapy. The immunohistochemical study revealed that epithelial cells, submucosal
glands, ﬁbroblast, vascular smooth muscle, vascular endothelial cells, and macrophages showed immunoreactivity for both B1 and
B2 receptors. The B2 receptor expression was found in peripheral nerve ﬁbers, whereas the B1 expression was not observed in
nerves. The results may have an important clinical implication for understanding the diﬀe r e n t i a lr o l e so fB Kr e c e p t o rs u b t y p e so n
upper airway diseases such as allergic rhinitis and nonallergic rhinitis.
Copyright © 2009 Hideaki Shirasaki et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
The allergic response is a complex process involving the
interaction of many mediators. Bradykinin (BK) is a potent
inﬂammatory mediator and its actions are mediated via
speciﬁc cell surface receptors which are coupled to G-
proteins. Two mammalian BK receptor subtypes, B1 and B2,
have been reported, and the amino acid sequence of the
B1 receptor is 36% identical to the amino acid sequence of
the B2 receptor [1]. Administration of exogenous BK into
human nasal airway causes nasal obstruction, rhinorrhea,
and nasal pain [2, 3]. These eﬀects appear to be mediated
by bradykinin B2 receptor because bradykinin B2 receptor
antagonists abolish bradykinin-induced nasal obstruction
andplasmaextravasation,whereasagonistsatthebradykinin
B1 receptor do not cause any symptoms [3]. Icatibant, a
bradykinin B2 receptor antagonist, inhibits the immediate
inﬂammatory response to antigen in subjects with perennial
allergicrhinitis[4,5].ThesereportssuggestthatBKmayplay
an important role in the pathogenesis of allergic rhinitis. The
previous autoradiograﬁc study using 125I-BK has demon-
stratedspeciﬁc 125I-BKbindingsitesmainlyexistonthesmall
muscular arteries, venous sinusoids, and submucosal ﬁbers
in human nasal mucosa [6]. However, there has been no
other report about BK receptor expression in upper airway.
In the present study, immunohistochemistry for brad-
ykinin B1 and B2 receptors was performed to conﬁrm the
expression and the distribution of these receptors in human
nasal mucosa.
2.MaterialsandMethods
2.1. Tissue Preparation. Human inferior turbinates were
obtained after turbinectomy from 12 patients with nasal
obstruction refractory to medical therapy. Informed consent
was obtained from all patients and this study was approved
by the ethics committee of Sapporo Medical University.
All were nonsmokers, and 6 patients had perennial allergy
against mites as deﬁned by questionnaire and CAP test
(Pharmacia, Uppsala, Sweden). All medications, including
antibiotics, were prohibited for at least 3 weeks prior to
the study. Demographic and clinical characteristics of the
patients are summarized in Table 1. The nasal mucosal2 Mediators of Inﬂammation
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Figure 1:ImmunohistochemicalstainingforbradykininB1receptorinhumanallergic(a),(c),(e)andnonallergic(b),(d),(f)nasalmucosa.
Inferior turbinates were stained with antihuman B1 receptor antibody (a)–(d) or normal rabbit immunoglobulin (e), (f). Immunoreactivity
for B1 receptor was signiﬁcantly detected in submucosal glands (a), (b), epithelial cells (a), (b), and ﬁbroblasts (c), (d). ep: epithelial cells; v:
blood vessels; g: submucosal glands; n: nerves. Scale bar = 100μm.
specimens were immediately ﬁxed in 10% formalin for
immunohistochemistry.
2.2. Immunohistochemistry
2.2.1.Antibodies. ForimmunohistochemistryofB1receptor,
rabbit antihuman B1 receptor polyclonal antibody against
a peptide corresponding to C-terminal domain of human
B1 receptor (catalog # LS-A3580, Lifespan Biosciences, Mich
USA) was used at 1:20 dilutions. Similarly, for immunohis-
tochemistry of B2 receptor, rabbit antihuman B2 receptor
polyclonal antibody against a peptide corresponding to C-
terminal domain of human B2 receptor (catalog # LS-
A797, Lifespan Biosciences, Mich, USA) was used at 1:100
dilutions. To identify the subsets of cells expressing each
bradykinin receptor, the following monoclonal antibodies
were used: anti-CD68 (KP-1 clone, Dako Corporation,
Carpinteria, Calif, USA) for macrophage, anti-CD31 (JC70A
clone, Dako) for vascular endothelial cells, antihuman
ﬁbroblast (5B5 clone, DAKO) for ﬁbroblast, anticytokeratin
(AE1/AE3 clone, Dako) for epithelial cells, and antineuroﬁl-
ament protein (2F11 clone, Dako) for peripheral nerves.
2.2.2. Immunohistochemistry. Deparaﬃnized sections were
initiallyincubatedwith3%H2O2 inmethanolfor10minutes
to quench endogenous peroxidase activity. After microwave
treatment (10 minutes at 500 Watt in citrate buﬀer), the
sections were incubated in blocking solution (10% normal
goat serum in PBS) for 30 minutes before incubation
in primary antibody. Then, the sections were incubated
with anti-bradykinin B1 or B2 polyclonal antibody for
overnight at 4◦C, washed, and incubated for 30 minutes with
EnVision+,Peroxidase(Dako).AfurtherwashinginPBSwas
followed by developing in DAB (Dako) as a chromogen for
signal visualization. The slides were counterstained Mayer’s
haematoxylin and coverslipped using mounting medium.Mediators of Inﬂammation 3
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Figure 2:ImmunohistochemicalstainingforbradykininB2receptorinhumanallergic(a),(c),(e)andnonallergic(b),(d),(f)nasalmucosa.
Inferior turbinates were stained with antihuman B2 receptor antibody (a)–(d) or normal rabbit immunoglobulin (e), (f). Immunoreactivity
for B2 receptor was signiﬁcantly detected in submucosal glands (), epithelial cells (c), vascular smooth muscle (c), (d), nerve bundle, and
ﬁbroblasts (d). ep: epithelial cells; v: blood vessels; g: submucosal glands; n: nerves. Scale bar = 100μm.
Table 1: Demographic characteristics of allergic and nonallergic
patients.
Allergic
rhinitis
Nonallergic
rhinitis
N = 6 N = 6
Sex (male/female) 2/4 3/3
Age 31(19–58) 39(28–55)
Speciﬁc IgE to house dust
mite (d1) (kU/L) 2.7(1.0–13) <0.35
Total IgE (kU/L) 210(10–387) 110(10–185)
Blood eosinophils (cells/μL) 370(70–690) 135(55–240)
Current nasal symptoms
(number of patients)
Nasal obstruction 6(all patients) 4(all patients)
Sneezing 4 0
Rhinorrhea 3 2
Data expressed as median values and range (in brankets).
Toidentifythesubsetsofcellsexpressingeachbradykinin
receptor, some sections were stained by immunoﬂuorescence
technique. For double staining, deparaﬃnized sections were
incubated overnight at 4◦C with a combination of rabbit
polyclonal antihuman bradykinin B1 or B2 antibody and
one of mouse monoclonal antihuman phenotypical makers
antibody. Sections were washed in PBS and were incubated
for 30 minutes with Alexa Fluor 594-labelled goat antimouse
IgG (diluted 1:50; Molecular Probes, Ore, USA) and Alexa
Fluor 488-labelled goat antirabbit IgG (diluted 1:50; Molec-
ular Probes). Sections were mounted with SlowFade antifade
kits (Molecular Probes) and examined under Olympus BX51
microscope, DP70 CCD camera (Olympus Optical Co.,
Tokyo, Japan). All images were processed with DP Controller
and DP Manager software (Olympus Optical Co) for image
analysis. Using this method, bradykinin B1 or B2 receptor
expressing cells was green, cellular phenotypical makers were
red, and the combined signal is visualized as yellow. Negative
controls were obtained by replacing primary antibodies by
mouse IgG1 and rabbit immunoglobulin fraction (Dako).
3. Results
As shown in Figure 1, the immunoreactivity for B1 receptor
was signiﬁcantly detected in submucosal glands, epithelial
cells (Figures 1(a), 1(b)), and ﬁbroblasts (Figures 1(c), 1(d)).
Immunoreactivity for B2 receptor was signiﬁcantly detected
in submucosal glands, epithelial cells (Figures 2(a), 2(b)),
vascular smooth muscle (Figures 2(c), 2(d)), nerve bundle,
andﬁbroblasts(Figures2(c),2(d)).Speciﬁcityofthestaining
was also conﬁrmed by the absence of labeling with normal
rabbit immunoglobulin (Figures 1(e) and 1(f)).
In order to clarify the cell expressing bradykinin B1
andB2receptors,weperformeddoubleimmunoﬂuorescence
staining. As shown in Figures 3 and 4, epithelial cells,
submucosal glands (Figures 3(b) and 4(b)), ﬁbroblast (Fig-
ures 3(d) and 4(d)), vascular smooth muscle, and vascular
endothelial cells (Figures 3(f) and 4(f)) express both B1 and
B2 receptors. The B2 receptor was found in nerve ﬁbers4 Mediators of Inﬂammation
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Figure 3: Identiﬁcation of subsets of cells expressing the B1 receptor in human allergic nasal mucosa. Single staining immunoﬂuorescence
for each cell type (panel (a), (c), (e), and (g) and the dual staining for the cell marker and B1 receptor (panel (b), (d), (f), and (h). The B1
receptor protein (green) shows colocalization with antiphenotypical marker antibody (red) and the combined signal is visualized as yellow.
Identiﬁcation markers for cytokeratin (epithelial cells) (a), (b); ﬁbroblast (c), (d); CD31 (vascular endothelial cells) (e), (f); neuroﬁlament
protein (peripheral nerves) (g), (h). Scale bar = 100μm.
(Figure 4(h)), whereas the B1 expression was not observed
in nerves (Figure 3(h)). As shown in Figure 5, the majority
ofCD68positive macrophagesshowedimmunoreactivityfor
both B1 and B2 receptors.
The expression levels of both B1 and B2 receptors on
epithelial cells and ﬁbroblast were higher in allergic nasal
mucosa (B1 receptor: Figures 1(a) and 1(c);B 2r e c e p t o r :
Figures 2(a) and 2(c)) than nonallergic nasal mucosa (B1
receptor:Figures1(b)and1(d);B2receptor:Figures2(b)and
2(d)).
The patterns of the other immunohistochemical ﬁnd-
ings in all 12 cases were remarkably similar, and we
could not ﬁnd any other diﬀerences of B1 and B2 recep-
tors immunoreactivity between on allergic and nonallergic
nasal mucosae. The summary of the results is shown in
Table 2.Mediators of Inﬂammation 5
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Figure 4: Identiﬁcation of subsets of cells expressing the B2 receptor in human allergic nasal mucosa. Single staining immunoﬂuorescence
for each cell type (panel (a), (c), (e), and (g) and the dual staining for the cell marker and B2 receptor (panel (b), (d), (f), and (h). The B2
receptor protein (green) shows colocalization with antiphenotypical marker antibody (red) and the combined signal is visualized as yellow.
Identiﬁcation markers for cytokeratin (epithelial cells) (a), (b); ﬁbroblast (c), (d); CD31 (vascular endothelial cells) (e), (f); neuroﬁlament
protein (peripheral nerves) (g), (h). Scale bar = 100μm.
4. Discussion
It is well known that the responses to vasoactive kinin pep-
tides are mediated through the activation of two receptors
termed B1 and B2, which have been deﬁned on the basis
of the structure-function relationships of their agonists and
antagonists [7]. The natural agonists of the B2-receptor are
the nonapeptide bradykinin (BK) and the decapeptide Lys-
BK (kallidin) which are generated by the proteolytic action
of the serine protease kallikrein from the protein precursor
kininogen [8]. BK and Lys-BK are weak B1 receptor agonist,
however, the cleavage of these two B2-agonists by arginine
carboxypeptidases produces the high aﬃnity B1 receptor
agonists, [des-Arg9]-BK, and [des-Arg10]-kallidin (DLBK),
respectively, [7]. The B1 receptor is not expressed at sig-
niﬁcant levels in normal tissues, but its synthesis can be
induced after tissue injury and by inﬂammatory factor such
as lipopolysaccharide and IL-1 beta [9]. On the other hand,6 Mediators of Inﬂammation
(a) (b)
(c) (d)
Figure 5: Expression of bradykinin B1 (a), (b) and B2 (c), (d) receptors on macrophages in human allergic nasal mucosa. (a) Macrophages
(CD68-positive cells) (red). (b) Overlay image of bradykinin B1 receptor protein (green) and macrophages (CD68-positive) (red). The
combinedsignalisvisualizedasyellow;(c)macrophages(CD68-positive)(red);(d)OverlayimageofbradykininB2receptorprotein(green);
macrophages (CD68-positive cells) (red). Scale bar = 50μm.
Table 2: Distribution pattern of B1 and B2 receptors in normal and
allergic nasal mucosae.
Normal nasal Allergic nasal
mucosa mucosa
B1 B2 B1 B2
Epithelium + + ++ ++
Submucosal gland + + + +
Nerve − ++ − ++
Fibroblast + + ++ ++
Vascular endothelial cell + + + +
Vascular smooth muscle + ++ + ++
Inﬂammatory cell (macrophage) ++ + ++ +
the B2 receptor is constitutively expressed in many types
of the cells including smooth muscle cells, certain neurons,
ﬁbroblasts, and epithelial cells of the lung.
In the present study, we conﬁrm the expression of both
bradykinin B1 and B2 receptors in human nasal epithelial
cells. BK induced rise in [Ca2+] in primary cultured human
nasal epithelial cells, suggesting the existence of B2 receptor
on human nasal epithelial cells [10]. B1 receptor ligand, Lys-
des-Arg-BK activated extracellular signal-regulated kinase
(ERK) and the transcription factor AP-1 in human airway
epithelial cell lines A549 and BEAS-2B [11]. Taken together,
these previous observations and our present observations
suggest the functional B1 and B2 receptors in human nasal
epithelial cells.
The present study indicated the signiﬁcant expression of
B1 and B2 receptor expressions on nasal ﬁbroblasts. It has
been reported that BK stimulated IL-1 [12], IL-6 [13], IL-
8[ 13, 14], and eotaxin [15] production in cultured human
ﬁbroblasts by increasing its gene expression. TNF-alpha and
IL-1beta both induced an increase in B1 and B2 receptor
expressions in human lung ﬁbroblasts [16]. The obser-
vation of local production of IL-1β during inﬂammation
accompanied by B1-receptor upregulation in several tissues
has resulted in the hypothesis that this cytokine is directly
involved in B1-receptor upregulation [9].
The expression of bradykinin B1 and B2 receptors were
found not only on epithelial cells and ﬁbroblasts, but
also on submucosal glands in the present study. It has
been reported that bradykinin receptors were detected over
submucosal gland in human and guinea pig airways by in
vitro autoradiography [17]. With respect to the eﬀect of BK
on airway submucosal glands, it has been reported that BK
directly stimulates isolated airway submucosal gland cells
and induces mucus glycoprotein and Cl− secretion through
the activation of B2 receptor [18]. Also, BK induces an
increase in short-circuit current across a cultured gland cell
layer from human airways with [Ca2+] rise, indicating a
direct stimulation of ion transport in airway gland cells
by BK [19]. On the other hand, some investigators have
reported that BK had no signiﬁcant eﬀect on mucin release
from human, feline, or ferret airway explants [6, 20].
In contrast to signiﬁcant both B1 and B2 receptor
expressions on epithelial cells, ﬁbroblasts, and submucosal
glands, B2 receptor expression on peripheral nerves, but notMediators of Inﬂammation 7
B1 receptor expression, could be detected by immunohisto-
chemistry. B1 receptor was thought to be generally absent
in healthy tissues [21, 22]. In contrast, B2 receptors are
constitutively expressed in a range of cell types including
sensory neurons, and their activation results in excitation
and sensitization of sensory neurons [23, 24]. In B2 receptor
agonist, BK can stimulate sensory nerve ending, causing the
release of substance P and other neuropeptides [25]. It has
been shown that the nasal stimulation with BK causes nasal
pain [2, 3], suggesting the existence of the functional B2
receptor on sensory nerves.
Using double immunoﬂuorescence technique, we could
conﬁrm the signiﬁcant expression of both B1 and B2 recep-
tors on macrophages. The potency of kinins to stimulate
leukocytes has been thought dependent on diﬀerentiation
and especially on the activation stage of these cells. The
diﬀerentiation of monocytes into macrophages is associ-
ated with functional and phenotypic changes. It has been
shown that human peripheral monocytes express a low
number of kinin B2 binding sites [26]. However, imma-
ture, unstimulated human monocytes-derived dendritic cells
constitutively express both B1 and B2 receptors, whereas
monocytes did not express B1 or B2 receptor protein [27],
suggesting upregulation of B1 and B2 receptors during the
diﬀerentiation of the cells. With respect to the eﬀect of
BK on monocytes, BK acting via B2 receptor, increased
intracelluar Ca2+, and stimulated the migration of immature
humanmonocyte-deriveddendriticcells[27].Thus,itmight
be possible that local macrophages might be activated by
locally released BK during nasal allergic response.
5. Conclusions
Using immunohistochemical technique, we have demon-
strated the distribution of bradykinin B1 and B2 receptors
in human nasal mucosa. Although kinins do not appear to
have major role in allergic rhinitis, our ﬁndings should be of
considerable interest for understanding the role of kinins on
upperairwaydiseasessuchasallergicrhinitisandnonallergic
rhinitis.
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